Program
ZM-H1505R
Also written as “ZM-H1505R 100mg”.
Its studies are mostly in Hepatitis B, Chronic, led by Shanghai Zhimeng Biopharma.
Furthest: phase 3, since Jul 14, 20254 company-led studies, 1 open or runningNext primary completion: Jan 2028 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Shanghai Zhimeng Biopharma | 41 open or running | phase 3since Jul 14, 2025 | Dec 23, 2019 | Jan 2028phase 3 · NCT07095855 |
Also a collaborator on its studies: Tigermed Consulting.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 23, 2019First study: phase 1 study in Healthy VolunteersFirst studyNCT04220801 · 64 enrolled · United States
- Jul 18, 2022Phase 1 study in Hepatitis B, ChronicNCT05470829 · 42 enrolled · China
- Jul 20, 2022Phase 2 study in Hepatitis B, ChronicNCT05484466 · 90 enrolled · China
- Jul 14, 2025Phase 3 study in Hepatitis B, ChronicNCT07095855 · 1,300 planned · China
Ahead
- Jan 2028Primary completion: phase 3 study in Hepatitis B, ChronicNCT07095855
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07095855Hepatitis B, Chronic · China | 3 | Not yet recruiting | Jan 2028 | 1,300 |
| NCT05484466Hepatitis B, Chronic · China | 2 | UNKNOWN | Dec 20, 2022 | 90 |
| NCT05470829Hepatitis B, Chronic · China | 1 | Completed | Nov 17, 2021 | 42 |
| NCT04220801Healthy Volunteers · United States | 1 | Completed | Nov 18, 2020 | 64 |
How it is read
Names in the registry
- “ZM-H1505R”, 3 entries
- “ZM-H1505R 100mg”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.